Current Osteoporosis Reports

, Volume 8, Issue 1, pp 28-33

First online:

Orthopedic Uses of Teriparatide

  • Susan V. BukataAffiliated withSchool of Medicine and Dentistry, University of Rochester Email author 
  • , J. Edward PuzasAffiliated withSchool of Medicine and Dentistry, University of Rochester

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblast-derived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis.


Orthopedic Teriparatide Fracture Osteoporosis Parathyroid hormone